NOV 16, 2017 05:20 AM PST

New Cancer Drug Approach Avoids Friendly Fire in the Immune System

WRITTEN BY: Kara Marker

With any cancer, developing treatments is difficult because cancer cells are an abnormal version of healthy cells. Any drug used to kill cancer cells runs the risk of killing healthy cells during the process. In the case of T cell lymphoma, the healthy cells that are at risk of friendly fire are vital cells of the immune system that are needed to defend the body from infection.

Subcutaneous panniculitis-like T-cell lymphoma. Credit: L. Wozniak & K.W. Zielinski

In collaboration with biopharmaceutical company Autolus Ltd, scientists from Cardiff University developed a new approach to treating T cell lymphoma, one that zeroes in on cancerous cells and keeps healthy T cells safe and fully-functioning.

As its name suggests, T cell lymphoma is a cancer the originates in abnormally growing T cells, a population of cells vital to a cell-mediated immune response that specifically targets incoming pathogens. Lymphoma is the most common type of blood cancer, and T cell lymphoma, a rare and usually aggressive cancer, accounts for 15 percent of all non-Hodgkin lymphoma cases in the United States.

"We wouldn't last a week without the essential job our T cells perform by protecting us from infection,” explained Cardiff University’s Andrew Sewell. “The devastating effects of low numbers of just one type of T cell are all too evident in HIV/AIDS.”

The new approach to treating T cell lymphoma is based on the two genes responsibel for creating the T cell receptor, a surface molecule that helps T cells recognize specific pathogens. A T cell is made by either the “C1” gene or the “C2” gene, and because cancer starts with a single cell, a whole tumor is either entirely made up of C1 T cells or of C2 T cells.

So, scientists decided to try and destroy T cells based on whether they were made by the C1 or C2 gene. In theory, they could target C1 T cells to kill C1 cancers while leaving C2 T cells alone, and vice versa. This eliminates the problem faced by scientists in the past looking for T cell lymphoma treatments, where telling the difference between healthy and cancerous T cells was tedious and not always accurate.

“Since T-cells select use of the C1 or C2 gene at random, this remaining half of T-cells are capable of providing immunity to the pathogens we encounter every day,” Sewell explained.

"This study has demonstrated it's possible to kill cancerous T-cells but importantly spare some healthy ones, opening up exciting new treatment possibilities,” said Cancer Research UK’s Dr. Justine Alford. “T cells are a vital part of our immune system and our survival.”

The present study was published in the journal Nature Medicine.

Source: Lymphoma Research Foundation, Cardiff University

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 13, 2019
Health & Medicine
NOV 13, 2019
Fourth-Generation Rapid Diagnostic Tests for Acute HIV-1 Infections
The ability to diagnose an acute HIV-1 infection before there are detectable antibodies to HIV 1/2 is critical to making an early diagnosis and getting the...
NOV 13, 2019
Cardiology
NOV 13, 2019
Opioid Addiction Comes With Increased Risk Of Infection
Public health officials have put decades of work into the battle against infectious diseases. Now, this progress is at risk of being dismantled. A recent s...
NOV 13, 2019
Cancer
NOV 13, 2019
How cancer tricks our immune systems
Research published yesterday in Nature details the finding of a new “Don’t eat me” signal that cancers use to hide from the body’s ...
NOV 13, 2019
Drug Discovery & Development
NOV 13, 2019
Researchers Can Now Reverse Skin Cancer
Ten years ago, just 5% of people with advanced melanoma (skin cancer) lived more than five years after being diagnosed. Now however, researchers from the I...
NOV 13, 2019
Neuroscience
NOV 13, 2019
Autism May be Linked to an Immune Disorder
Until now, diagnosis for autism spectrum disorder have relied on behavioral assessments looking for symptoms including poor social and communication skills...
NOV 13, 2019
Immunology
NOV 13, 2019
Immunity to HPV Can Prevent Skin Cancer
Scientists discovered a surprise benefit of low-risk human papillomaviruses (HPV), a typical resident of human skin. New research shows that these harmless...
Loading Comments...